Skip to content
news
Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results...
Oct 10, 2024
Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize...
Oct 8, 2024
Lipocine to Host Virtual KOL Event on LPCN 2401 for...
Oct 2, 2024
Company
About Lipocine
Management
Board of Directors
Corporate Governance
Careers
Pipeline & Product
Pipeline
LPCN 1154
LPCN 2101
LPCN 2401
LPCN 1148
LPCN 1107
LPCN 2203
LPCN 1154
LPCN 2101
LPCN 2401
LPCN 1148
LPCN 1107
LPCN 2203
Product
TLANDO®
TLANDO® Product Site
TLANDO®
TLANDO® Product Site
Technology
Li’pral Technology
Li’pral Technology
Investors/Media
Press Releases
Presentations/Events
SEC Filings
Investor FAQ
Contact
Address & Inquiries
Business Development
Linkedin-in
Search
Investors/Media
Investors/Media
Recent press releasees
View All
October 10, 2024
Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results
Read More
October 8, 2024
Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO® in the Gulf Cooperation Council (GCC) Countries
Read More
October 2, 2024
Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024
Read More
August 27, 2024
Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference
Read More
August 8, 2024
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2024
Read More
August 6, 2024
Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154
Read More
View All
Presentations
View All
LPCN 1144 Presentation
View
LPCN 1148 Phase 2 Study Topline Results
View
LPCN 1148 Presentation
View
View All
Events
View All
September 30, 2024
Lipocine to Present at H.C. Wainwright 8th Annual MASH Investor Conference
Read More
September 5, 2024
Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek®
Read More
View All
Focus on enhancing health
We are pioneers of developing innovative drug products targeting significant unmet medical needs.